Recent high profile reports of Cannabidiol (a natural non-psychoactive component of marijuana) being very effective in treating otherwise intractable seizure disorders have led to families of severely affected children demanding access, but current laws in most countries make both access and controlled research difficult. How can this be better managed both clinically and for research?